Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global ...

Murdo Gordon, Executive Vice President of Global Commercial Operations at Amgen Inc . (NASDAQ:AMGN), recently sold a significant portion of the company's stock. According to a filing with the ...

Citi analyst Geoff Meacham maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $295.00. The company’s ...

The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...

Samsara is the IBD Stock of the Day ahead of its Q4 earnings report due March 6. Samara stock has forged a cup base, rebounding from a sell-off.

People who have trouble breathing as they sleep often turn to ResMed, which makes a face-worn breathing apparatus. Its ...

Jonathan P. Graham, Executive Vice President and General Counsel at Amgen Inc . (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $158 billion and "GOOD" financial ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...